Pfizer Inc. (PFE) Stock Price Prediction

Target vs 52-Week Range

Pfizer Inc. is a leading global biopharmaceutical company navigating a transition period following the peak of its COVID-19 product revenues. The company reported better-than-expected Q1 2026 earnings, with an adjusted EPS of $0.75 and revenues of $14.5 billion, exceeding analyst estimates. This performance was driven by a 7% operational growth in non-COVID products and a 22% increase from recently launched and acquired products. Pfizer is strategically repositioning itself in high-growth therapeutic areas, particularly oncology through the Seagen acquisition, and entering the obesity market via the Metsera deal. Despite reaffirming its full-year 2026 financial guidance, the company faces a significant patent cliff between 2026 and 2028, potentially impacting annual revenues by $17-18 billion. Pfizer maintains a robust R&D pipeline with 102 programs in development and 96 active Phase 3 trials, aimed at offsetting these upcoming losses.

Recent technical analysis indicates a bearish sentiment for PFE, with the stock price trading below the 21-, 50-, and 100-day Simple Moving Averages (SMAs). The MACD (Moving Average Convergence Divergence) also confirms ongoing selling pressure. Key support levels are identified between $23.00 and $23.62. A break below these levels could lead to further declines towards $22.00 or potentially $20.00. Over the past year, the stock has shown a modest 2.9% increase, underperforming the broader industry's 17.2% gain.

Pfizer's AI price target of $28.50 suggests a potential upside from its current price, aligning with a "Hold" consensus rating from 14 analysts and an average price target of $28.50. Analyst price targets range from $25 to $30, indicating a cautious but generally stable outlook. A key upcoming event is the Q2 2026 earnings report, expected on August 4, 2026, where analysts forecast an EPS of $0.68. Pfizer is strategically focusing on oncology, obesity, and new product launches to drive future growth, with several pivotal studies underway for drugs like berobenatide for weight management and expanded indications for PADCEV in bladder cancer. The company recently received FDA approval for PADCEV plus Keytruda for muscle-invasive bladder cancer, which supports its oncology growth narrative. Furthermore, Pfizer's CEO has indicated a shift away from large acquisitions to focus on leveraging artificial intelligence for drug discovery and operational enhancement. Investors should be aware that price targets are estimates and actual performance can vary.